SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?


To: celeryroot.com who wrote (1119)9/10/1999 9:02:00 PM
From: Scott H. Davis  Respond to of 1972
 
Good question, I can't find anything either. Bigger vol than recently, but not a real large chunk. I continue to see accumulation in several biotechs (TTP has been going gonzos on strong vol with not recent since July, look at IMCL) Enough clinical probress & terchnical strength that folks think the water in the biotech pool is safe again? Money moving to other sectors after the Inut drop? Some short covering?
ISIP's broken out of it's 1 year declining trendline, and close to a 2 year breakout. Mostly clueless, Scott



To: celeryroot.com who wrote (1119)9/10/1999 11:32:00 PM
From: Scott H. Davis  Respond to of 1972
 
CR, I looked for news, forgot to check the chart. Look at where VICl stood going into today.

siliconinvestor.com

ViCL had been hitting 15 as a point of resistance several times, but each time from a progressively higher base. Technically this is an ascending triangle, a bullish pattern which I have found to be a fairly good predictor of an upside breakout.

And the nice thing now is that the stock is nowhere near overbought. Should be more upside room, especially if we get some more good news and/or coverage. IMSCO Scott



To: celeryroot.com who wrote (1119)9/11/1999 11:44:00 PM
From: Scott H. Davis  Read Replies (1) | Respond to of 1972
 
One very positive result of the recent runnup is that VICL will now probably escape the tax loss selling that plagued it last two falls, since the strong majority of the shares purchased this year are at a gain, plus a lot from last year. IMSCO Scott



To: celeryroot.com who wrote (1119)10/27/1999 6:40:00 PM
From: Scott H. Davis  Read Replies (1) | Respond to of 1972
 
Vical drug wins orphan status from FDA. biz.yahoo.com